Citius Pharmaceuticals Inc

CTXRNASDAQ · USD
0.53USD0.00 (-1.41%)
325

Citius Pharmaceuticals Inc (CTXR) Covered Calls

Read more

Running CTXR covered calls helps you generate income from Citius Pharmaceuticals Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CTXR covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If CTXR stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CTXR covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CTXR covered call is worth writing.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.

No illustrative rows to display.

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank63.49% Moderate
  • Market cap (M$)14
  • 52 weeks high-65.58%
  • 52 weeks low43.24%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$4.00
    654.72% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-12-22
  • P/E—
  • Future P/E—
  • EPS (ttm)-2.11
  • EPS growth next 5 years41.69%

As of Nov 16, 2026